Search

Your search keyword '"Waxman I"' showing total 335 results

Search Constraints

Start Over You searched for: Author "Waxman I" Remove constraint Author: "Waxman I"
335 results on '"Waxman I"'

Search Results

1. Volumetric laser endomicroscopy and its application to Barrett's esophagus: results from a 1,000 patient registry

3. 1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

13. Perceptions of risk and therapy among patients with Barrett's esophagus: a patient survey study.

14. Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): results of a phase III study (CheckMate 066)

16. Randomized, Dose-Ranging Phase Ii Trial of Nivolumab for Metastatic Renal Cell Carcinoma (Mrcc)

20. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients

21. Endomicroscopie confocale par minisondes (ECM) guidée par échoendoscopie: résultats préliminaires d'une étude multicentrique internationale chez 58 patients présentant une tumeur kystique du pancréas (Protocole INSPECT)

22. Intravenous (IV) Busulfan (Bu) Administered Twice Daily During Conditioning Prior to Allogeneic Stem Cell Transplant (AlloSCT) in Pediatric Recipients Has Significantly Different Half-Life of Elimination and Clearance in Recipients >4 Years and Those ≤ 4 Years

23. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents

25. Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial

26. Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial

27. Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population

28. Preliminary results of gemtuzumab ozogamicin (GO) during myeloablative conditioning for allogeneic stem cell transplantation (AlloSCT) or following reduced intensity alloSCT (RI-AlloSCT) in children with AML

29. 229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

30. 202: Preliminary Results of a Phase I Study of Immuno-Chemotherapy (CTX) Conditioning with Gemtuzumab Ozogamicin (GO), Busulfan (Bu) and Cyclophosphamide (Cy) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) in Pediatric Recipients with High Risk (HR) CD33+ Acute Myelogenous Leukemia (AML)

34. Clinical Impact of Conventional Endosonography and Endoscopic Ultrasound-guided Fine-needle Aspiration in the Assessment of Patients with Barrett’s Esophagus and High-grade Dysplasia or Intramucosal Carcinoma who have been Referred for Endoscopic Ablation Therapy

35. Double Balloon Enteroscopy

46. Feasibility of a novel system for intraductal balloon-anchored direct peroral cholangioscopy and endotherapy with an ultraslim endoscope (with videos)

50. What is the learning curve associated with double-balloon enteroscopy? Technical details and early experience in 6 U.S. tertiary care centers.

Catalog

Books, media, physical & digital resources